For healthRX’s research roundup, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
Last spring, a family medicine physician named Rachel in suburban Phoenix told me something that stuck. She’d been in practice since 2008. “I spent fifteen years telling patients the same thing,” she said. “Diet, exercise, maybe phentermine for a few months. Then the GLP-1 data started coming in, and I realized I’d been offering people a garden hose for a house fire.” Her clinic had tripled its weight-management referrals in eighteen months. She was rewriting intake forms she hadn’t touched in a decade.
Rachel’s experience isn’t unique. The past five years have forced a reckoning across obesity medicine, and the speed of it has caught even well-informed clinicians off guard. What changed isn’t just the drugs. It’s the scale of their effect, the quality of the trial data behind them, and the downstream shift in how the entire field talks about body weight.
This is the condensed version of how we got here.
Amphetamines, Fen-Phen, and the Scar Tissue of Past Mistakes
Pharmacologic treatment of obesity has a history you could charitably call “uneven.” Amphetamines were handed out like candy through the 1950s and 1960s, with results that were fast, temporary, and frequently disastrous. Physicians prescribed them for everything from mild weight gain to post-pregnancy body changes, often without defined endpoints or discontinuation plans. Dependence and cardiovascular events piled up. By the time the DEA tightened scheduling in 1971, millions of patients had already cycled through prescriptions that were never designed for long-term use.
Then came fen-phen, the combination of fenfluramine and phentermine that hit enormous prescription volume in the 1990s before being yanked from the market in 1997 over heart-valve damage and pulmonary hypertension. At its peak, roughly 6.6 million Americans had received fen-phen prescriptions in a single year, according to FDA estimates at the time. The Mayo Clinic report that identified valvular heart disease in 24 women taking the combination was published in the New England Journal of Medicine in 1997 and set off a cascade of withdrawals, lawsuits, and regulatory tightening that reshaped how the agency evaluated every obesity drug that followed.
Those episodes left deep institutional scars. Every time a new weight-loss drug appeared after 1997, the FDA and the clinical community looked at it through fen-phen-colored glasses. That caution was earned. It also slowed adoption of agents that deserved a more open hearing. Sibutramine, approved in 1997, was pulled in 2010 after the SCOUT trial showed increased cardiovascular event risk. Rimonabant, approved in Europe but never in the U.S., was withdrawn in 2008 over psychiatric adverse effects including suicidal ideation. Each failure reinforced the narrative that weight-loss drugs were inherently dangerous, a narrative that was partially correct and entirely unhelpful for patients who needed pharmacologic options.
See also: The Future of Interactive Entertainment Technologies
Phentermine Hung Around Longer Than It Probably Should Have
Phentermine, approved in 1959, remained one of the most prescribed weight-loss medications in the United States through the early 2010s. Think about that for a moment. An Eisenhower-era sympathomimetic appetite suppressant was still the go-to pharmacologic tool more than fifty years later. It worked in the short term. Tolerance developed. Blood pressure crept up. Long-term outcome data never materialized in any convincing form.
The typical prescription pattern told the story. A patient would get a 12-week supply, lose eight to twelve pounds, hit a plateau, and stop the medication. Most regained the weight within a year. A 2019 analysis published in Obesity found that real-world weight loss with phentermine averaged about 5% of baseline body weight at six months, with most of that effect eroding after discontinuation. The field didn’t move past phentermine because something better arrived. It moved past phentermine because eventually the lack of evidence became impossible to ignore, and because patients themselves started asking why the only tool on the shelf was the same one their mothers had been prescribed.
Orlistat: Good Mechanism, Miserable Experience
Orlistat, approved in 1999, took a completely different approach. Block dietary fat absorption in the gut. The pharmacology was sound. The XENDOS trial, published in Diabetes Care in 2004, showed that orlistat reduced the incidence of type 2 diabetes by 37% over four years in patients with obesity and impaired glucose tolerance. On paper, a meaningful result.
The gastrointestinal side effects were brutal enough that most patients quit before the drug had time to work. Steatorrhea, oily spotting, fecal urgency: these weren’t rare adverse events buried in fine print. They were the daily experience for a significant fraction of users, particularly those who didn’t adhere to strict dietary fat limits. Adherence at one year in real-world settings ran well below trial levels. Orlistat remains available, including in an over-the-counter formulation. It never came close to the prescription volume its early projections anticipated, and the reasons were sitting in patient bathrooms across the country.
Surgery Set the Benchmark
For decades, bariatric surgery was the only intervention that produced substantial, durable weight loss. Sleeve gastrectomy, Roux-en-Y gastric bypass: these procedures delivered results no pill could match. The Swedish Obese Subjects (SOS) study, with follow-up extending past 20 years, showed sustained weight loss of roughly 18% for gastric bypass patients and significant reductions in cardiovascular mortality, cancer incidence, and type 2 diabetes onset. No pharmacologic agent came within shouting distance of those outcomes until very recently.
Here’s the thing that gets overlooked, though. Many of the mechanisms behind bariatric surgery’s success involve changes in gut hormone signaling, including elevated post-meal GLP-1 levels. Post-surgical patients show markedly increased GLP-1 secretion after eating, which suppresses appetite, slows gastric emptying, and enhances insulin sensitivity. The convergence between what surgery does hormonally and what the new medications do pharmacologically is not a coincidence. They’re addressing the same biology from opposite directions. The conversation in obesity medicine increasingly treats them as complementary tools rather than competing ones, with some clinicians using GLP-1 receptor agonists to manage weight regain after bariatric procedures.
The Incretin Drugs Arrive, Slowly Then All at Once
Exenatide, the first synthetic GLP-1 receptor agonist, was approved by the FDA in 2005 for type 2 diabetes. Nobody was calling it a weight-loss drug. It was derived from a peptide found in Gila monster saliva, which is exactly the kind of origin story that gets buried once a drug class reaches blockbuster status. Liraglutide followed in 2010 with daily dosing and a clearer weight signal. The SCALE trials demonstrated roughly 8% body weight loss at one year with liraglutide 3.0 mg daily, a step up from anything phentermine or orlistat had managed, though the daily injection burden limited enthusiasm.
Then semaglutide arrived in 2017, and was approved for weight management at the 2.4 mg weekly dose in 2021 under the brand name Wegovy. The STEP 1 trial, published in the New England Journal of Medicine in 2021, showed a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo. The SELECT trial, published in 2023, demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity but without diabetes. That cardiovascular signal changed the risk-benefit conversation entirely.
Each step in that chain extended dosing intervals, improved tolerability, and increased the magnitude of weight effect. The jump was dramatic. The realistic expectation for pharmacologic weight loss went from roughly five percent of body weight to the mid double digits. That’s not an incremental improvement. That’s a different category of intervention.
Tirzepatide, a dual GIP/GLP-1 receptor agonist approved under the brand name Zepbound for weight management in 2023, pushed the numbers further. The SURMOUNT-1 trial reported mean weight loss of 22.5% at 72 weeks with the highest dose. These are figures that overlap with surgical outcomes for the first time in the history of pharmacologic obesity treatment.
The Patients Changed, Too
The patient population walking into weight-management clinics today looks different from five years ago. People who would have been given a pamphlet and a handshake are now arriving with specific questions about specific molecules. They’ve read trial abstracts. They’ve watched their neighbors lose forty pounds. They want to know about titration schedules and nausea management and what happens when you stop.
The clinical conversation has had to get sharper in response. Generic advice about willpower and portion control doesn’t survive contact with a patient who can quote STEP trial data from their phone. Clinicians who haven’t updated their knowledge base since residency are finding themselves behind their own patients, which is an uncomfortable but ultimately productive dynamic.
Chronic Disease, Not Moral Failure
The arrival of effective, well-tolerated medications pushed clinical framing toward treating obesity as a chronic disease. This isn’t marketing spin. A medication that requires ongoing dosing for ongoing effect, that produces measurable physiologic change, and that has documented cardiovascular benefit fits the chronic-disease model. It fits the model the way statins fit the model for hyperlipidemia, or ACE inhibitors fit it for hypertension. The older framing, built around willpower and personal responsibility, doesn’t survive the pharmacology.
The STEP 1 trial extension data made this point clearly. Participants who discontinued semaglutide after 68 weeks regained approximately two-thirds of their lost weight within a year. That pattern is consistent with treating a chronic condition, not curing one. It’s the same pattern you’d see with blood pressure medication: the drug works while you take it, and the disease reasserts itself when you stop.
That said, let me be blunt about what we don’t know yet. The field has been confidently wrong before. Fen-phen looked safe and effective right up until the moment it didn’t. The GLP-1 trial data are solid through several years of follow-up. The five-year, ten-year, twenty-year questions are still being answered. Patients deserve to hear which questions are settled (short-to-medium-term efficacy, cardiovascular benefit in certain populations) and which ones are genuinely open (lifetime dosing implications, outcomes after discontinuation at scale, effects in populations underrepresented in trials). Clinical humility is appropriate even when the current data are the strongest we’ve ever had in this field.
Drugs Don’t Work Alone
Pharmacologic therapy doesn’t exist in a vacuum. Bariatric surgery, intensive behavioral therapy, structured nutrition counseling, exercise programming, sleep medicine, mental health care: all of these have legitimate roles. The patients who do best tend to be the ones whose care teams treat these as complementary rather than competing, with sequencing matched to the individual. Medication without behavioral support often works. Medication with behavioral support tends to work better and last longer. (That observation applies to most chronic-disease management, frankly.)
A practical example: patients on GLP-1 receptor agonists who also engage in resistance training tend to preserve more lean mass during weight loss, which matters for metabolic rate, functional capacity, and long-term weight maintenance. The medication reduces appetite and caloric intake. The exercise protects the tissue you want to keep. Neither intervention fully substitutes for the other.
What Comes Next
A reader looking for a deeper companion reference can review HealthRX’s research roundup, which lays out the dosing, safety, and program-level material in more detail than a historical survey like this one allows.
The literature is still developing quickly. Five-year follow-up data are accumulating. Long-term retention curves are starting to appear in published form. Comparative outcomes across different programs and medications are being studied with more rigor than the field managed in earlier eras. The clinical recommendations of 2028 will look somewhat different from those of 2026, and that’s a sign the science is functioning as it should.
Until the long-term evidence catches up with current prescribing volume, careful titration and honest reporting of side effects remain the two most useful tools any patient has. Those aren’t glamorous recommendations. They’re the boring truth, and the boring truth tends to age well.
FAQ
What was wrong with fen-phen specifically? Fenfluramine and dexfenfluramine were found to cause serotonin-mediated damage to heart valves and pulmonary arterial hypertension. The FDA withdrew both in September 1997. Phentermine alone was not implicated in the valve findings and remains available today, though its evidence base for long-term use is thin.
How is semaglutide different from older weight-loss drugs? Semaglutide is a GLP-1 receptor agonist that mimics a naturally occurring gut hormone. It reduces appetite through central nervous system pathways, slows gastric emptying, and improves glycemic control. Older drugs like phentermine acted primarily as sympathomimetic stimulants with a narrower mechanism and a shorter evidence trail. The trial data supporting semaglutide’s efficacy and cardiovascular benefit are substantially larger and more rigorous than anything available for prior agents.
Do people regain weight after stopping GLP-1 medications? Yes. The STEP 1 extension data showed that participants who stopped semaglutide after 68 weeks regained about two-thirds of their lost weight within 12 months. This is consistent with obesity being a chronic condition requiring ongoing treatment, similar to how blood pressure rises when antihypertensive medication is discontinued.
Is bariatric surgery still relevant if medications this effective exist? Very much so. Surgery remains the most effective single intervention for severe obesity and has the longest follow-up data. It is also increasingly used alongside pharmacologic therapy. Some patients use GLP-1 receptor agonists to manage weight regain after surgery. The two approaches target overlapping biology and are best understood as part of the same toolkit rather than as alternatives.
What are the most common side effects of GLP-1 receptor agonists? Nausea, vomiting, diarrhea, and constipation are the most frequently reported. These tend to be most pronounced during dose titration and often diminish over several weeks. Slow, stepwise dose increases are the standard approach to managing gastrointestinal tolerability. Less common but more serious concerns include pancreatitis and, in preclinical animal studies, medullary thyroid carcinoma, though the relevance of the thyroid finding to humans remains under investigation.
How long has GLP-1 receptor agonist data been accumulating? Exenatide was approved in 2005, so the drug class has nearly two decades of clinical use in diabetes populations. Semaglutide specifically has been studied since the mid-2010s. The SELECT cardiovascular outcomes trial published data through a median follow-up of roughly 40 months. Longer-duration studies are ongoing, and the field will need that data before confident statements about truly long-term safety can be made.
What should I look for when evaluating a weight-management program or provider? Look for providers who discuss evidence-based options including behavioral therapy, nutrition, exercise, medication, and surgery as appropriate. Be cautious of programs that promise specific weight-loss percentages, skip medical screening, or avoid discussing side effects. HealthRX, for example, is LegitScript-certified, which provides a layer of third-party verification for online health platforms. Ask whether the program includes follow-up protocols, titration guidance, and a clear plan for what happens if you discontinue treatment.
Not FDA-approved. HealthRX is not a medical practice. Individual results vary.
